Abstract: A "single-use" personal care product designed to replace conventional single use products such as small bars of soap, mini-bottles of shampoo, etc. A water soluble foamed polymer structure, such as produced by freeze drying acemannan derived from aloe vera, serves as the carrier for the personal care active ingredient, and provides the bulk to the structure. The dry foamed product has high void volume, good dimensional stability, high surface area, dissolves easily and completely upon exposure to water and hand mechanical action, and leaves no adverse residue on the skin. The product does not require bottling or complex wrapping, and is much more economical and environmentally friendly than the conventional single use products it replaces. The product can be conveniently carried in a purse or pocket, so that a consumer need never be without his/her favorite personal care products.

Abstract: Sustained release dosage forms of high dose insoluble drugs such as ibuprofen and methods for their manufacture are disclosed.

Abstract: A pharmaceutical composition of a water soluble drug admixed with an aqueous bioadhesive cellulosic polymer containing microcrystalline particles. When sprayed (via a conventional spray device) into the nose, drug molecules are retained in contact with the nasal membrane. The drug composition comprises ketorolac tromethamine in an aqueous nasal polymeric spray formulation that without the addition of any permeation enhancer will promote drug absorption and provides absolute drug bioavailability greater than 90%.

Abstract: A stable dry powder skin care powder having prolonged and controlled release properties, useful as baby powders, body talcs, deodorizing powders, OTC eczema preparations, foot powders, anti-fungal powders, etc. The dry powder is preferably prepared by a process comprising spray-drying a mixture of liposome encapsulated active agent, starch and maltodextrin. The particle is designed so that activity of, e.g., an anti-inflammatory agent such as Dragosantol.RTM. can be specifically triggered by skin conditions, such as moisture, for optimal timing of delivery.

Abstract: A biologically active composition comprising a solution of an active agent dissolved in a glass-forming carrier, which carrier comprises a glass-forming substance (A) containing a plasticizer (B), the amount of plasticizer preferably being selected so that the composition has a non-solid consistency. The composition can be prepared by dissolving the active agent in a melted mixture of the glass-forming substance and the plasticizer at a temperature below the decomposition temperature of said active agent. Use of the glass-forming carrier for dissolving a biologically active agent.

Abstract: The present invention provides, inter alia, formulations useful to ameliorate symptoms associated with mucosal abrasions, specifically those due to dental orthodontic brackets; oral surgery; periodontal surgery or other procedures. For instance, there is a formulation comprising: 65 to 75% microcrystalline wax; 5 to 15% non-ionic polymer; 15 to 25% topical anesthetic; and 1 to 5% surfactant, wherein the ratio of non-ionic polymer to microcrystalline wax is no greater than 0.2. Preferably, for solid topical anesthetics, the particle size is less than the apertures of a 100-mesh screen. However, the topical anesthetic may also be a liquid. Formulations wherein the mixture is a homogeneous matrix is preferred.

Abstract: The present invention contemplates a composition and method for treating a bacterial infection in a mammal. Comprising/administering a therapeutically effective amount of a peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

Abstract: This invention is directed to a novel solid matrixed controlled release, oral dosage form where the dosage form contains a therapeutically effective amount of a sulfonylurea or a salt or derivative thereof in the matrix. Further, the use of an aqueous alkalizing medium affords substantially complete bioavailability of the drug from the matrix of the tablet. The core tablets may optionally be coated with a coating material in the range of 2% to 10% with an enteric material or with a water insoluble material like ethyl cellulose.

Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.

Abstract: Anhydrous cosmetic stick formulations such as lip balms, lipsticks, and underarm deodorant or antiperspirant sticks, comprising an organic matrix having particles homogeneously dispersed therein, which particles are preferably prepared by a process comprising spray-drying a mixture of liposome encapsulated active agent, modified starch, and optionally a hydrocolloid gum such as maltodextrin.

Abstract: A biocompatible monomer composition includes at least one monomer, which forms a medically acceptable polymer, and an effective amount of at least one heat dissipating agent sufficient to reduce exothermic polymerization temperature increase of the composition. The heat dissipating agent enhances patient comfort and prevents necrosis of living tissue normally encountered with such medical adhesives.

Abstract: A crosslinkable macromer system that includes two or more polymer-pendent polymerizable groups and one or more polymer-pendent initiator groups. The polymerizable groups and the initiator group(s) can be pendent on the same or different polymeric backbones. The macromer system provides advantages over the use of polymerizable macromers and separate, low molecular weight initiators, including advantages with respect to such properties as nontoxicity, efficiency, and solubility.

Abstract: Methods for enhancing the stability of thickening agent solutions, especially guar solutions, by sterilizing the solution with UV light and/or adding a surfactant to the solution are disclosed. Thickening agent solutions and powders, including guar solutions and powders, as well as products made from these solutions and powders, are also disclosed.

Abstract: A topical, transdermal anesthetic comprising a eutectic mixture of, preferably, lidocaine and prilocaine in a ratio of about 3:1 by weight, incorporated within a lipophilic base. In addition to the property of rapid-onset, the formulation of the present invention has high storage stability and is less restricted by dosage limitations of other prilocaine-containing transdermal anesthetics and is, advantageously, not dependent upon occlusive dressing for optimal transdermal absorption.

Abstract: A bolus for supplying a biologically beneficial substance to a ruminant animal, which includes a binder constituted by a rosin matrix, preferably pine rosin, together with a ballast material, such a zinc, with the biologically beneficial substance being dispersed in the binder, so that, in use, the biologically beneficial substance is released by leaching from the non-eroding body of the bolus. A pocket may be included in the body of the rosin bolus, which pocket erodes to release an additional biologically beneficial substance.

Abstract: The invention provides a shelf-life extender for upholding the freshness of food, such as meat, vegetables, fruits, etc., in retail packages or in a refrigerator for an extended period of time. An isothiocyanic acid compound is supported on a matrix such as a natural mucilaginous polysaccharide or a solid organic acid and the supported compound is packaged in synthetic resin film or nonwoven fabric. The invention further provides an aqueous gel composition comprising a specified surfactant, an isothiocyanic acid compound, and a gelling agent and a hydrophobic gel composition comprising a specified hydrophobic dispersion medium, an isothiocyanic acid compound, and a gelling agent.

Abstract: Process is provided for preparing an oral solid rapidly disintegrating freeze-dried dosage form of a pharmaceutically active substance having an unacceptable taste, wherein prior to freeze drying, a suspension of uncoated or coated coarse particles of a pharmaceutically active substance in a carrier material is cooled to reduce the viscosity and minimize release of the active substance during processing, as well as beyond the point of disintegration of the form in the mouth, to minimize bad taste from the drug.

Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.

Abstract: Single and multiple layer membranes such as gloves and condoms include one or more deactivating barrier layers and/or indicating layers to indicate to a user membrane breach or the presence of a harmful substance in blood or body fluids. A membrane may include one or more permeable or semipermeable layers to disperse contained substances such as lubricants, biocides, spermicides, or indicators outwardly, and may also include permeable or semipermeable layers to allow transmission of body fluids or other environmental fluids inwardly into contact with an indicating or treating substance. An intermediate layer of a multi-layer membrane may include a substance to wipe, cleanse, sterilize, or otherwise treat a piercing needle. A membrane may include a sealing or coating to entrap indicators or other agents such as biocides therein. A method of making membranes such as gloves results in a double glove having discrete inner or outer layers joined only in a cuff region.

Abstract: A protective cosmetic particulate gel delivery system for a topically applied active agent employs an agar gel and a restraining polymer to retain the actve agent in the gel. The particles have an average particle diameter of at least 0.05 mm while the restraining polymer has a molecular weight of at least 50,000 daltons and has retention groups to bind the active agent. The restraining polymers can be selected from the group consisting of polyquaternium 24, laurdimonium hydroxyethylcellulose, cocodimonium hydroxyethylcellulose, steardimonium hydroxyethylcellulose, quaternary ammonium substituted water-soluble polysaccharides, alleyl quaternary celluloses and polypeptides having or provided with retention groups to retain the active agent. The gel particles of the invention are manually crushable on the skin to increase the surface area of the gel particle material and expose the restraining polymer to the skin or other body surface for release of the active agent.

Abstract: A coating for a drug wherein said coating is formed from seaweed and/or kelp, the seaweed and/or kelp being of a type which is impervious to gastric acidity but denaturable by alkali found in the intestines. Suitably, the coating comprises a capsule which also incorporates a binder or the coating may comprise barium sulfate or other acid-resistant bulking agents.

Abstract: The present invention concerns a new branched natural soluble polysaccharide comprising a main chain having repeating side chains which are only made of lactose units, possibly substituted.The present invention also concerns the microorganism by which this branched polysaccharide may be obtained and the food composition, the cosmetical composition and the pharmaceutical composition comprising said branched polysaccharide and/or microorganism.

Abstract: A readily, water-dispersible pesticide formulation in the form of a thick paste containing 1 to 80% by weight of the pesticide, 0.30 to 2.0% by weight of a micropore-generating agent and 30 to 50% by weight of effervescent agents the percentages being based on the total weight of the formulation.

Abstract: A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

Abstract: Disclosed are budesonide pellets with a controlled release pattern containing, from the inside to the outside: a) neutral pellets; b) an active principle layer of micronized budesonide and one or more water-soluble auxiliaries; c) a first lacquer coating consisting of 80 to 97% of at least one lacquer insoluble in gastric fluids but soluble in intestinal fluids and 3 to 20% of at least one lacquer insoluble in both gastric and intestinal fluids; and d) a second lacquer coating consisting of at least one lacquer insoluble in gastric and intestinal fluids. The invention also relates to a process for producing budesonide pellets with a controlled release pattern.

Abstract: A composite for retarding, killing, preventing or controlling microbiological contamination includes a hydrophilic material containing an .alpha.-amino ether, .alpha.-amino alcohol or .alpha.-amino ester and a chlorite salt, and a hydrophobic material containing an acid releasing agent. The hydrophilic and hydrophobic materials are adjacent and substantially free of water, and the hydrophilic material is capable of generating and releasing chlorine dioxide after hydrolysis of the acid releasing agent.

Abstract: Provided is an herbal extract-based composition comprising an extract of Gynostemma pentaphyllum, an extract of Crataegus pinnatifida (hawthorn leaves or berries), and an extract of Camellia sinensis (green tea). Also provided is a process for preparing a herbal extract-based composition which comprises separately extracting each of hawthorn berries, green tea leaves, and Gynostemma pentaphyllum leaves; drying extraction eluates obtained from the extracting of each of hawthorn berries, green tea leaves, and Gynostemma pentaphyllum leaves to obtain organic residues in forming a hawthorn berry extract powder, green tea extract powder, and a Gynostemma pentaphyllum extract powder; and combining the green tea extract powder, the Gynostemma pentaphyllum extract powder, and the hawthorn berry extract powder in desired proportions to form the herbal extract-based composition which has health promoting effects including potent inhibition of free radicals.

Abstract: Methods of forming solid pharmaceutical compositions comprise solubilizing water-soluble polymers and amino acid-based components having molecular weights ranging from about 100 daltons to about 200,000 daltons or pharmaceutically acceptable salts thereof in solvents; and separating the solvents from the water-soluble polymers and the amino acid-based components or pharmaceutically acceptable salts thereof to form solid pharmaceutical compositions comprising the water-soluble polymers and the amino acid-based components or pharmaceutically acceptable salts thereof.

Abstract: Controlled release compositions of matter are disclosed comprising complexes for treating a population of one or more aquatic organisms in a column of water. The complexes comprise at least one system wherein the system comprises at least one bioactive agent as a component selected for treating a population of aquatic organisms, at least one carrier component, and at least one coating component for regulating the controlled release rate and release profile of the bioactive agent in water or at least one bioactive agent and one joint-function component that can serve as both a carrier and coating to regulate the controlled release rate and release profile of the bioactive agent in water, with or without optional binder components and/or additional formulation materials. The components are selected to sink or float so that the complexes will permeate and/or remain in any planar or volumetric segment of a water column for a period of time that is sufficient to effectively treat a population of aquatic organisms.

Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.

Abstract: This invention relates to novel biopesticidal compositions comprising an active insecticidal ingredient selected from insecticidal bacteria and viruses such as B. thuringiensis crystal protein or spores or mixtures thereof and baculoviruses such as nuclear polyhedrosis viruses, granulosis viruses and non-occluded viruses; a polymer; and an inorganic light blocking agent wherein the light blocking agent protects the active ingredient from both ultraviolet light and sunlight and the polymer forms a matrix in which the active ingredient and light blocking agent are dispersed therein. Methods for producing the biopesticidal compositions and methods of controlling insects are also included within the scope of the invention.

Abstract: Controlled release compositions of matter are disclosed comprising complexes for treating a population of one or more aquatic organisms in a column of water. The complexes comprise at least one system wherein the system comprises at least one bioactive agent as a component selected for treating a population of aquatic organisms, at least one carrier component, and at least one coating component for regulating the controlled release rate and release profile of the bioactive agent in water or at least one bioactive agent and one joint-function component that can serve as both a carrier and coating to regulate the controlled. release rate and release profile of the bioactive agent in water, with or without optional binder components and/or additional formulation materials.

Abstract: An antimicrobial agent comprising allyl isothiocyanate (AIT) packaged in a packaging material having a structure wherein part of the pores of a porous packaging substrate is filled with, or said pores are partially or entirely narrowed by a resin impervious to AIT vapor, and a method for controlling the AIT vapor release speed comprising enclosing AIT in the above-mentioned packaging material. According to the present invention, the AIT vapor release speed can be controlled, whereby enabling sustained release of AIT vapor and persistent effect of antimicrobial action. In addition, the antimicrobial agent of the present invention can be widely applied to food industries and various other fields where breeding and reproduction of deleterious microorganisms pose problems, since it is economical, compact and easy to use.

Abstract: Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer. Methods of preparing the polymeric drug formulations are also described, as well as methods for site-specific drug delivery utilizing the polymeric drug formulations.

Abstract: Methods are provided for the treatment of a host suffering from a cellular proliferative disease through administration of a chemotherapeutic agent in conjunction with a cell membrane permeant. Optionally, the cell membrane permeant and/or chemotherapeutic agent will be present in a pharmaceutically acceptable vehicle capable of acting as a depot. In the subject methods, the chemotherapeutic agent and membrane permeant are administered at least proximal to a target site of the host. Administration of chemotherapeutic agents in accordance with the subject methods results in improved efficacy of, and/or decreased host toxicity to, the intralesionally administered chemotherapeutic agent.

Abstract: Controlled release compositions of matter are disclosed comprising complexes for treating a population of one or more aquatic organisms in a column of water. The complexes comprise at least one system wherein the system comprises at least one bioactive agent as a component selected for treating a population of aquatic organisms, at least one carrier component, and at least one coating component for regulating the controlled release rate and release profile of the bioactive agent in water or at least one bioactive agent and one joint-function component that can serve as both a carrier and coating to regulate the controlled release rate and release profile of the bioactive agent in water, with or without optional binder components and/or additional formulation materials. The components are selected to sink or float so that the complexes will permeate and/or remain in any planar or volumetric segment of a water column for a period of time that is sufficient to effectively treat a population of aquatic organisms.

Abstract: A stable gelled composition is provided which can contain a large amount of electrolyte and which contains, as gelling agent, a polysaccharide alkyl ether formed from units containing at least two different monosaccharides, each unit containing at least one saturated alkyl ether group. The polysaccharide alkyl ether preferably has a molecular weight of greater than 200,000 and is in particular a guar gum alkyl ether having a degree of substitution of approximately 2 to 3, preferably about 2.5. The composition obtained can be used in the cosmetics and/or dermatological fields for the treatment and care of the skin, scalp, mucous membranes, nails and hair.

Abstract: A controlled-release pharmaceutical preparation comprising diamorphine, or a pharmaceutically acceptable salt thereof.

Abstract: Process for the preparation of shaped, compressed controlled-release unit-dosage forms from a therapeutic active substance exhibiting a self-retarding release that depends on the magnitude of the force used for the compression. The process gives unit-dosage forms for which the release of the active substance is highly uniform, reproducibly identical and largely linear. To achieve this, the active substance and an additive charge that inhibits or compensates for the self-retardation of its release are processed into particles in the first stage of production, so that the preliminary compressed objects made from these particles without any further additives exhibit a rapid release (in comparison with the required controlled release) over the range of the force of compression envisaged for the production of the unit-dosage form in question, after which the particles are compressed in the second stage of production with a release-retarding agent to obtain the unit-dosage forms.

Abstract: A process for the preparation of an oral solid rapidly disintegrating dosage form of a pharmaceutically active substance which has an unacceptable taste which process comprises forming a solution or a suspension in a solvent of a form of the pharmaceutically active substance which is less soluble in water and more palatable than the form with the unacceptable taste together with a water-soluble or water-dispersible carrier material, forming discrete units of the suspension or solution and removing the solvent from the discrete units under conditions whereby a network of the carrier material carrying a dosage of the less soluble and more palatable form of the pharmaceutically active substance is formed.

Abstract: The invention provides a dendrimeric compound comprising a dendrimeric bioactive moiety with linked thereto a plurality of diagnostically or therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.

Abstract: An microparticle composition and its method of use in drug delivery and diagnostic applications are disclosed. Also disclosed are methods of storing and administering drug compounds at high concentration in condensed-phase microparticles.

Abstract: Pharmaceutical compositions for orally delivering a therapeutically effective amount of a drug to the colon without significant release of the drug in the upper GI tract after oral administration of the composition are described. The composition is a unit dosage in the form of a tablet that comprises about 0.01% by weight to about 10% by weight of the drug that is useful in treating a colonic disorder or that is absorbed from the colon; about 40% by weight to about 98% by weight of a hydrocolloid gum obtainable from higher plants; and about 2% by weight to about 50% by weight of a pharmaceutically acceptable binder. The compositions are useful for treating lower GI disorders in human subjects by administering a suitable amount to a subject in need thereof. A particularly preferred aspect is the process for preparing such composition in the form of a tablet.

Abstract: Drugs are delivered in a sustained manner from an in vivo depot which is formed from a collagen-based injectable composition. The injectable composition is fluid when injected but undergoes crosslinking in situ to form a crosslinked collagen matrix which encloses the drug to be released. The composition also includes a flexible chain polymer which is similarly charged to the precrosslinked collagen. This flexible chain polymer is enclosed in the matrix as well when the matrix forms and alters the effective porosity of the matrix. The drug diffuses out of the matrix at a rate which depends upon the matrix's effective porosity.

Abstract: A method for releasing molecules (guest molecules) from the matrix formed by the structure of another molecule (host molecule) in a controllable manner has been invented. This method has many applications in science and industry. In addition, applications based on such molecular systems may revolutionize significant areas of medicine, in particular the treatment of cancer and of viral infection. Similar effects can also be obtained by controlled fragmentation of a source molecule, where the molecular fragments form the active principle.

Abstract: A ruminant feed additive composition comprises a phosphoric acid-amino acid composite salt and a water-insoluble salt of a polyvalent-metal-sensitive water-soluble high-molecular weight substance. The composite salt contains a basic amino acid, an alkaline-earth metal and phosphoric acid, and is insoluble in neutral or alkaline aqueous solution, but is soluble in acidic aqueous solution.

Abstract: A stable dry powder skin care powder having prolonged and controlled release properties, useful as baby powders, body talcs, deodorizing powders, OTC eczema preparations, foot powders, anti-fungal powders, etc. The dry powder is preferably prepared by a process comprising spray-drying a mixture of liposome encapsulated active agent, starch and maltodextrin. The particle is designed so that activity of, e.g., an anti-inflammatory agent such as Dragosantol.RTM. can be specifically triggered by skin conditions, such as moisture, for optimal timing of delivery.

Abstract: A pharmaceutically acceptable liquid suspension system is provided for solid finely divided pharmaceutical actives incompletely soluble in water, the suspension system comprising water, xanthan gum and hydroxypropyl methylcellulose.

Abstract: There is disclosed a solid fast dispersing dosage form of a pharmaceutical composition suitable for oral administration comprising: a therapeutic agent which comprises one or more compound thyroid hormone or hormones; from about 80% to about 99.9% of disintegrating agent by mass; from about 0.01% to about 10% of flavoring agent by mass; and from about 0.1% to about 5% mass of lubricating agent by mass; which has utility in the treatment of disorders associated with the improvement of the thyroid hormone function in animals including human beings.

Abstract: Release of an active ingredient can be controlled and the active ingredient can be protected from the environment during storage, by distributing it throughout a matrix containing a relatively large amount of polymeric material that is soluble and swellable in aqueous alkali but less soluble and swellable at a lower pH value and which is in the form of a dried oil-in-water emulsion of the polymer or a relatively insoluble partial salt of the polymer with a volatile amine, the full salt of the polymer being relatively soluble. The composition is of particular value for the protection of detergent enzymes.